Isatuximab After Allogeneic Stem Cell Transplant

Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation

  • Transplant Service
  • 23-119

Arms / Cohorts

Experimental:Patients with Refractory Immune Cytopenias

Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.